GSK gets option to OncoMed's cancer stem cell antibodies; terminated
GlaxoSmithKline's Center of Excellence for External Drug Discovery has agreed to option four of start-up OncoMed Pharmaceuticals's monoclonal antibodies--including lead OMP21M18 in preclinical studies--against cancer stem cells.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.